Nuvilex, Inc. (OTC:NVLX) Skips Up Again
Here is a company that is bent on eradicating sickness, and one that promises to make investors rich and happy- Nuvilex, Inc. (OTC:NVLX) stands at 8 cents after another good daily climb, adding 14% late last week. The latest email from April 18th named the company as highly undervalued. We will see how the beginning of a new week affects NVLX, but the past months show a steady upward trend, supported by regular press releases. 
NVLX tried its hand at many business models, from advanced drug development to the promising, yet risky field of medical marijuana. To achieve its goals and continue operations, NVLX can rely on the following resources: 
- $33,000 cash
- $1.4 million current assets
- $3.6 million current liabilities
- Zero revenues
- $376 thousand quarterly net loss
This is the typical picture of a drug developing company that has taken too ambitious a task, in this case- taking a shot at treating pancreatic cancer and diabetes. While the development of these treatments is still in the pipeline, NVLX added medical marijuana to the mix, and we are not certain whether it is the medical potential or the business potential that matters more. Some of its previous attempts at greatness include easy to remove tattoo ink, a formula to boost the immune system and cosmetic treatments for scars.
But the greatest success comes from promotions and press releases. The company even managed to get the Forbes logo on its publication, although the text was written by a small analyst firm, Stone Street Advisors, LLC, and not a Forbes staff reporter. Premiere Alerts, the pumper that received $2,500 to mention NVLX, has a long record of past picks that show what may happen to NVLX. Indeed, it’s surprising that NVLX has not sunk to rock-bottom three-zero prices with so many promotions and keeps a respectable position at a few cents.
One of the previous picks of Premiere Alerts is Creative Edge Nutrition, Inc. (OTC:FITX). The chart easily shows that the ticker shot up in price and volumes at the end of March, when the emails were received, but went on to slide by 50% in the days after. It is best to be aware that most of the NVLX talk is a bit exaggerated, and may cause disproportionate interest and stock movements. While this ticker holds relatively well, it is still advised to expect significant falls and not invest sums you could not afford to lose.
